ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR oktober 9, 20170OpmerkingenEN Read More
ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting september 27, 20170OpmerkingenEN Read More
ThromboGenics Provides Business and Clinical Update at European and US Investor Meetings september 21, 20170OpmerkingenEN Read More
ThromboGenics Regains Global Rights to JETREA® (ocriplasmin) september 18, 20170OpmerkingenEN Read More
ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB september 1, 20170OpmerkingenEN Read More
New Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 in Boston augustus 16, 20170OpmerkingenEN Read More
ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement juli 10, 20170OpmerkingenEN Read More
Tussentijds Financieel Verslag – Halfjaarcijfers per 30 juni 2017 juni 30, 20170OpmerkingenTussentijds Financieel Verslag – Halfjaarcijfers per 30 juni 2017 Read More
Interim Financial Report – First Half Year Results per 30 June 2017 juni 30, 20170OpmerkingenInterim Financial Report – First Half Year Results per 30 June 2017 Read More
ThromboGenics jaarresultaten 2015 – presentatie december 30, 20150OpmerkingenThromboGenics jaarresultaten 2015 - presentatie Read More
ThromboGenics jaarresultaten 2015 – transcriptie december 30, 20150OpmerkingenThromboGenics jaarresultaten 2015 - transcriptie Read More
Tussentijds Financieel Verslag – Halfjaarcijfers per 30 juni 2015 juni 30, 20150OpmerkingenTussentijds Financieel Verslag – Halfjaarcijfers per 30 juni 2015 Read More
ThromboGenics halfjaarresultaten 2015 – transcriptie van de call juni 30, 20150OpmerkingenThromboGenics halfjaarresultaten 2015 - transcriptie van de call Read More
Interim Financial Report – First Half Year Results 2015 juni 30, 20150OpmerkingenInterim Financial Report – First Half Year Results 2015 Read More
